1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480–486. [PubMed] 2. Lloyd-Jones DM, Hong Y, Labarthe D, et al. American Heart Association Strategic Planning Task Force and Statistics Committee Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association’s Strategic Impact Goal Through 2020 and Beyond. Circulation. 2010;121(4):586–613. [PubMed]
3. Kones R, Phillips JH. Prevention of Heart Cell Death. In: Yu PN, Goodwin JF, editors. Progress In Cardiology. Vol. 4. Philadelphia, PA: Lea and Febiger; 1975. pp. 199–224.
4. Hyattsville, MD: National Center for Health Statistics; 2010. Health, United States, 2009: with special feature on medical technology; p. F38.
6. Fuster V, Kelly BB, editors. for the Institute of Medicine (US) Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the challenges in developing countries, promoting cardiovascular health in the developing world: a critical challenge to achieve global health. Washington, DC: National Academies Press (US); 2010 The National Academies Collection: Reports funded by National Institutes of Health.
7. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association. Circulation. 2011;123(8):933–944. [PubMed] 8. Capewell S, Ford ES, Croft JB, Critchley JA, Greenlund KJ, Labarthe DR. Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. Bull World Health Organ. 2010;88(2):120–130. [PubMed] 9. Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity and smoking on US life expectancy. N Engl J Med. 2009;361(23):2252–2260. [PubMed]
10. Crimmins EM, Preston SH, Cohen B, editors. Explaining Divergent Levels of Longevity in High-Income Countries. Washington, DC: The National Academies Press; 2011. Panel on Understanding Divergent Trends in Longevity in High-Income Countries; Report of the National Research Council of the National Academies.
11. Kones R. Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention. Ther Adv Cardiovasc Dis. 2011;5(1):61–81. [PubMed] 12. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368(9536):647–658. [PubMed] 13. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation. 2008;118(5):576–585. [PubMed] 14. The Lp-PLA2 Studies Collaboration Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 studies. Lancet. 2010;375(9725):1536–1544. [PMC free article] [PubMed] 15. Kones R. Rosuvastatin, inflammation, C-reactive Protein, JUPITER, and primary prevention of cardiovascular disease – a perspective. Drug Des Devel Ther. 2010;4:383–413. [PMC free article] [PubMed] 16. Pearson TA. The prevention of cardiovascular disease: Have we really made progress? Health Aff (Millwood) 2007;26(1):49–60. [PubMed] 17. Hemenway D. Why We Don’t Spend Enough on Public Health. New Eng J Med. 2010;362(18):1657–1658. [PubMed] 18. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the US. N Engl J Med. 2003;348(26):2635–2645. [PubMed] 20. Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the US by improvements in use of clinical preventive services. Am J Prev Med. 2010;38(6):684–685. [PubMed]
21. National Institute of Health and Clinical Excellence NICE Public Health Guidance 25: Prevention of Cardiovascular Disease at Population Level. London, UK: National Institute of Health and Clinical Excellence; 2010.
22. Strasser T. Reflections on cardiovascular diseases. Interdiscip Sci Rev. 1978;3:225–230.
23. Pippin JJ. Primary Prevention Cardiovascular Disease: Better Than Drugs. Arch Intern Med. 2010;170(20):1860–1861. [PubMed]
24. De Lorgeril M, Salen P, Rabeus M. Primary Prevention Cardiovascular Disease: Better Than Drugs – Reply. Arch Intern Med. 2010;1861;170(20)
25. Armstrong ML, Megan MB. Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res. 1972;30(6):675–680. [PubMed] 26. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease: five-year follow-up of the Lifestyle Heart Trial. JAMA. 1998;280(23):2001–2007. [PubMed] 27. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791–798. [PubMed] 28. Kullo IJ, Cooper LT. Early identification of cardiovascular risk using genomics and proteomics. Nat Rev Cardiol. 2010;7(6):309–317. [PMC free article] [PubMed] 29. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925–1932. [PubMed] 30. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev. 2011;1:CD001561. [PubMed] 31. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur Heart J. 2007;28(19):2375–2414. [PubMed]
32. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2010;56(25):2182–2199.
33. Institute of Medicine Crossing the Quality Chasm: A New Health System for the Twenty-first Century. Washington, DC: National Academy Press; 2001.
34. Brindis R, Spertus JA. President’s Page: Employing shared decision-making models to improve care and patient value: A cardiovascular Professional initiative. J Am Coll Cardiol. 2010;56(24):2046–2048. [PubMed]
35. White S. Effectiveness of public health and education programs for creating awareness of and managing cardiovascular disease. Patient Intelligence. 2011;3:11–21.
37. Finucane MM, Stevens GA, Cowan MJ, et al. on behalf of the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377(9765):557–567. [PubMed] 38. Farzadfar F, Finucane MM, Danaei G, et al. on behalf of the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Cholesterol) National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3·0 million participants. Lancet. 2011;377(9765):578–586. [PubMed] 39. Danaei G, Finucane MM, Lin JK, et al. on behalf of the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure) National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. Lancet. 2011;377(9765):568–577. [PubMed] 40. Anand SS, Yusuf S. Stemming the global tsunami of cardiovascular disease. Lancet. 2011;377(9765):529–532. [PubMed] 41. Capewell S, Hayes DK, Ford ES, et al. Life-years gained among US adults from modern treatments and changes in the prevalence of 6 coronary heart disease risk factors between 1980 and 2000. Am J Epidemiol. 2009;170(2):229–236. [PubMed] 42. Björck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J. 2009;30(9):1046–1056. [PubMed] 43. Young F, Capewell S, Ford ES, Critchley JA. Coronary Mortality Declines in the US Between 1980 and 2000. Quantifying the Contributions from Primary and Secondary Prevention. Amer J Prev Med. 2010;39(3):228–234. [PubMed]
44. USDHHS, National Center for Health Statistics Second National Health and Nutrition Examination Survey (NHANES II) Hyattsville, MD: CDC; pp. 1976–1980.
45. USDHHS, National Center for Health Statistics Second National Health and Nutrition Examination Survey (Continuous NHANES) Hyattsville, MD: CDC; pp. 1999–2002.
46. Briffa TG, Hobbs MS, Tonkin A, et al. Population trends of recurrent coronary heart disease event rates remain high. Circ Cardiovasc Qual Outcomes. 2011;4(1):107–113. [PubMed]
47. Rose G. The Strategy of Preventive Medicine. Oxford, UK: Oxford University Press; 1992.
48. Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J (Clin Res Ed) 1981;282(6279):1847–1851. [PMC free article] [PubMed] 49. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14(1):32–38. [PubMed]
50. Rose G. Strategies of prevention: the individual and the population. In: Marmot M, Elliott P, editors. Coronary Heart Disease Epidemiology: From Aetiology to Public Health. Oxford, UK: Oxford University Press; 1991. pp. 631–641.
51. Hingorani AD, Psaty BM. Primary Prevention of Cardiovascular Disease. Time to Get More or Less Personal? JAMA. 2009;302(19):2144–2145. [PubMed] 52. Berger JS, Jordan CO, Lloyd-Jones DM, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol. 2010;55(12):1169–1177. [PubMed] 53. Fryar CD, Hirsch R, Eberhardt MS, Yoon SS, Wright JD. Hyattsville, MD: National Center for Health Statistics; Apr 26, 2010. Hypertension, high serum total cholesterol, and diabetes: Racial and ethnic prevalence differences in US adults, 1999–2006. NCHS data brief, no 36. Available at: http://www.cdc.gov/nchs/default.htm. Accessed March 24, 2011. [PubMed] 54. Roger VL, Go AS, Lloyd-Jones DM, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Committee Heart Disease and Stroke Statistics–2011 Update: A Report From the American Heart Association. Circulation. 2011;123(4):e18–e209. [PubMed] 55. Paez KA, Zhao L, Hwang W. Rising Out-Of-Pocket Spending For Chronic Conditions: A Ten-Year Trend. Health Aff (Millwood) 2009;28(1):15–25. [PubMed] 56. Levi J, Vinter S, St Laurent R, Segal LM. F as in Fat 2010 Finds Continued Rise in Nation’s Obesity Rates. Jun 29, 2010. Trust for America’s Health, and the Robert Wood Johnson Foundation. Available at: http://www.rwjf.org/pr/product.jsp?id=65469. Accessed March 24, 2011. 57. Barnes PM, Heyman KM, Freeman G, Schiller JS. Early release of selected estimates based on data from the 2009 National Health Interview Survey. Hyattsville, MD: National Center for Health Statistics; Jun 16, 2010. Available at: http://www.cdc.gov/nchs/nhis.htm. Accessed March 24, 2011. 60. Huang ES, Basu A, O’grady M, Capretta JC. Projecting the Future Diabetes Population Size and Related Costs For The US. Diab Care. 2009;32(12):2225–2229. [PMC free article] [PubMed] 61. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Population Health Metrics. 2010;8:29. [PMC free article] [PubMed] 62. Yancy CW. Is Ideal Cardiovascular Health Attainable? Circulation. 2011;123(8):835–837. [PubMed] 63. Kones R. Low-fat versus low-carbohydrate diets, weight loss, vascular health, and prevention of coronary artery disease: the evidence, the reality, the challenge, and the hope. Nutr Clin Pract. 2010;25(5):528–541. [PubMed] 64. Heber D. An integrated view of obesity. Am J Clin Nutr. 2010;91(1):280S–283S. [PubMed] 65. Bray GA. Let’s treat obesity seriously. Amer Fam Physician. 2010;81(12):1449–1455. [PubMed] 67. Danaei G, Friedman AB, Oza S, Murray CJL, Ezzati M. Diabetes prevalence and diagnosis in US states: analysis of health surveys. Popul Health Metr. 2009;7:16. [PMC free article] [PubMed] 68. Hammond RA, Levine R. The economic impact of obesity in the United States. Diabetes Metab Syndr Obes. 2010;3:285–295. [PMC free article] [PubMed]
69. Vickers MH, SLoboda DM. Prenatal nutritional influences on obesity risk in offspring. Nutrition and Dietary Supplements. 2010;2:137–149.
70. Ford ES, Li C, Zhao G, Tsai J. Trends in obesity and abdominal obesity among adults in the United States from 1999–2008. Int J Obes (Lond) 2011;35:736–743. [PubMed] 71. Bambs C, Kip KE, Dinga A, Mulukutla SR, Aiyer AN, Reis SE. Low Prevalence of “Ideal Cardiovascular Health” in a Community-Based Population: The Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) Study. Circulation. 2011;123(8):850–857. [PMC free article] [PubMed] 73. Sacker A, Head J, Bartley M. Impact of coronary heart disease on health functioning in an aging population: are there differences according to socioeconomic position? Psychosom Med. 2008;70(2):133–140. [PubMed] 76. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the US from 1980 to 2002: concealed leveling or mortality rates. J Am Coll Cardiol. 2007;50(22):2128–2132. [PubMed] 77. Ayer J, Steinbeck K. Placing the cardiovascular risk of childhood obesity in perspective. Int J Obes. 2010;34(1):4–5. [PubMed] 78. Berenson G. Cardiovascular health promotion for children: A model for a Parish (County)-wide program (implementation and preliminary results. Prev Cardiol. 2010;13(1):23–28. [PubMed] 80. Berenson GS, Srinivasan SR. Cardiovascular Risk in Young Persons: Secondary or Primordial Prevention? Ann Int Med. 2010;153(3):202–203. [PubMed] 81. Pletcher MJ, Bibbins-Domingo K, Liu K, et al. Nonoptimal lipids commonly present in young adults and coronary calcium later in life: The CARDIA (Coronary Artery Risk Development in Young Adults) Study. Ann Intern Med. 2010;153(3):137–146. [PMC free article] [PubMed] 82. Falk E, Naghavi M, Shah PK. Legislating screening for atherosclerosis. JAMA. 2008;299(18):2147–2148. [PubMed] 84. Kuklina E, Shaw KM, Y Hong Y. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol – United States, 1999–2002 and 2005–2008. MMWR. 2011;60(04):109–114. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm60e0201a2.htm. Accessed March 24, 2011. [PubMed]
85. Katch H, Mead H. The role of self-efficacy in cardiovascular disease self-management: a review of effective programs. Patient Intelligence. 2010;2:33–44.
86. Bosworth HB. Challenges and strategies to improve patient health literacy and competencies. Patient Intelligence. 2010;2:19–25.
87. McNeal TM, Colbert CY, Cable C, et al. Patients’ attention to and understanding of adverse drug reaction warnings. Patient Intelligence. 2010;2:59–68.
88. Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adherence. Eur Heart J. 2011;32(3):264–268. [PubMed] 89. Fischer MA, Stedman MR, Lii J, et al. Primary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions. J Gen Int Med. 2010;25(4):284–290. [PMC free article] [PubMed] 90. Lardizabal JA, Deedwania PC. Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag. 2010;6:843–853. [PMC free article] [PubMed] 91. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence isassociated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772–729. [PubMed] 92. Donnelly LA, Doney AS, Morris AD, Palmer CN, Connan PT. Long-term adherence to statin treatment in diabetes. Diabet Med. 2008;25(7):850–855. [PubMed] 93. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE Study Group Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929–940. [PubMed] 94. Popkin BM. Recent dynamics suggest selected countries catching up to US obesity. Am J Clin Nutr. 2010;91(1):284S–288S. [PubMed] 95. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. [PubMed] 96. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293–301. [PubMed] 97. Simmons RK, Unwin N, Griffin SJ. International Diabetes Federation: An update of the evidence concerning the prevention of type 2 diabetes. Diabetes Res Clin Pract. 2010;87(2):143–149. [PubMed] 98. Joshi R, Jan S, Wu Y, MacMahon S. Global inequalities in access to cardiovascular health care: our greatest challenge. J Am Coll Cardiol. 2008;52(23):1817–1825. [PubMed] 99. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER-HEART study): case-control study. Lancet. 2004;364(9438):937–952. [PubMed] 100. Reddy KS, Prabhakaran D, Jeemon P, et al. Educational status and cardiovascular risk profile in Indians. Proc Natl Acad Sci U S A. 2007;104:16263–16268. [PubMed] 101. Franco M, Cooper RS, Bilal U, Fuster V. Challenges and opportunities for cardiovascular disease prevention. Amer J Med. 2011;124(2):95–102. [PubMed] 102. Kavey E-RW, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003;107(11):1562–1566. [PubMed] 103. McMahan CA, Gidding SS, Viikari JSA, et al. Association of Pathobiologic determinants of atherosclerosis in youth risk score and 15-year change in risk score with carotid artery intima–media thickness in young adults (from the Cardiovascular Risk in Young Finns Study) Am J Cardiol. 2007;100(7):1124–1129. [PMC free article] [PubMed] 104. Shah AS, Dolan LM, Kimball TR, et al. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94(10):3740–3745. [PubMed] 105. Newman WP, Wattigney W, Berenson GS. Autopsy studies in United States children and adolescents: relationship of risk factors to atherosclerotic lesions. Ann N Y Acad Sci. 1991;623:16–25. [PubMed] 106. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999;281(8):727–735. [PubMed] 107. Corvalán C, Uauy R, Kain J, Martorell R. Obesity indicators and cardiometabolic status in 4-y-old children. Am J Clin Nutr. 2010;91(1):166–174. [PubMed] 108. Mauras N, DelGiorno C, Kollman C, et al. Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab. 2010;95(3):1060–1068. [PubMed] 109. Milei J, Ottaviani G, Lavezzi AM, Grana DR, Stella I, Matturi L. Perinatal and infant early atherosclerotic coronary lesions. Can J Cardiol. 2008;24(2):137–141. [PMC free article] [PubMed] 110. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001;103(22):2705–2710. [PubMed] 111. Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea: preliminary report. JAMA. 1953;552(12):1090–1093. [PubMed] 112. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA. 1971;216(7):1185–1887. [PubMed] 113. Newman WP, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study. N Engl J Med. 1986;314(3):138–144. [PubMed] 114. Berenson GS, Srinivasan SR, Bao W, Newman WP, 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med. 1998;338(23):1650–1656. [PubMed] 115. Nguyen QMN, Srinivasan SR, Xu J-H, Chen W, Kieltyka L, Berenson GS. Utility of childhood glucose homeostasis variables in predicting adult diabetes and related cardiometabolic risk factors. Diabetes Care. 2010;33(3):670–675. [PMC free article] [PubMed] 116. Berenson GS, Wattigney WA, Tracy RE, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study) Am J Cardiol. 1992;70(9):851–858. [PubMed] 117. Berenson GS. Cardiovascular risk begins in childhood. A time for action. Am J Prev Med. 2009;37(1 Suppl):S1–S2. [PubMed] 118. Twisk JW, Kemper HC, Mellenbergh GJ. Mathematical and analytical aspects of tracking. Epidemiol Rev. 1994;16(2):165–182. [PubMed] 119. García RG, Pérez M, Maas R, Schwedhelm E, Boger RH, Lopez-Jaramillo P. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol. 2007;122(2):176–178. [PubMed] 120. Gillum RF. Association of serum C-reactive protein and body fat distribution and overweight in Mexican American children. J Natl Med Assoc. 2003;95(7):545–552. [PMC free article] [PubMed] 121. López-Jaramillo P, Herrera E, García RG, Camacho PA, Castillo VR. Relationship of body mass index, C-reactive protein and blood pressure in a Hispanic pediatric population. Am J Hypertens. 2008;21(5):527–532. [PubMed] 122. Magnussen CG, Thomson R, Cleland VJ, Ukoumunne OC, Dwyer T, Venn A. Factors affecting the stability of blood lipid and lipoprotein levels from youth to adulthood: evidence from the Childhood Determinants of Adult Health Study. Arch Pediatr Adolesc Med. 2011;165(1):68–76. [PubMed] 123. PDAY Research Group Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: a preliminary report from the Pathological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264(23):3018–3024. [PubMed] 124. Wissler RW, Strong JP., the PDAY Research Group Risk factors and progression of atherosclerosis in youth. Am J Pathol. 1998;153(4):1023–1033. [PubMed] 125. McGill HC, Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study. Circulation. 2008;117(9):1216–1227. [PubMed]
126. McGill HC, McMahan CA. Starting early to control all risk factors in order to prevent coronary heart disease. Clinical Lipidol. 2010;5(1):87–93.
127. Juonala M, Viikari JSA, Kähönen M, et al. Life-time risk factors and progression of carotid atherosclerosis in young adults: the Cardiovascular Risk in Young Finns study. Eur Heart J. 2010;31(14):1745–1751. [PubMed] 128. Juonala M, Magnussen CG, Venn A, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: The Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation. 2010;122(24):2514–2520. [PubMed] 129. Gidding SS. Assembling evidence to justify prevention of atherosclerosis beginning in youth. Circulation. 2010;122(24):2493–2494. [PubMed] 130. Daniels SR, Greer FR., Committee on Nutrition Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122(1):198–208. [PubMed] 131. O’Gorman CSM, O’Neill MB, Conwell LS. Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. Vasc Health Risk Manag. 2011;7:1–14. [PMC free article] [PubMed]
132. Cohen H, Stein-Zamir C, Hamiel O, et al. Israeli guidelines for the management of hypercholesterolemia in children and adolescents. Report of the pediatric association expert group. e-SPEN. Eur e-Journal Clin Nutr Metabol. 2010;5(3):e132–e143.
133. Iughetti L, Bruzzi P, Predieri B. Evaluation and management of hyperlipidemia in children and adolescents. Curr Opin Ped. 2010;22(4):485–493. [PubMed] 134. Gooding HC, D de Ferranti S. Cardiovascular risk assessment and cholesterol management in adolescents: getting to the heart of the matter. Curr Opin Ped. 2010;22(4):398–404. [PMC free article] [PubMed] 135. Wierzbicki AS, Viljoen A. Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice. Drug Safety. 2010;33(2):115–125. [PubMed] 136. Lebenthal Y, Horvath A, Dziechciarz P, Szajewska H, Shamir R. Are treatment targets for hypercholesterolemia evidence based? Systematic review and meta-analysis of randomised controlled trials. Arch Dis Child. 2010;95(9):673–680. [PubMed] 137. De Ferranti S, Ludwig DS. Storm over Statins – The Controversy Surrounding Pharmacologic Treatment of Children. N Engl J Med. 2008;359(13):1309–1312. [PubMed] 138. Steinberg D, Glass CK, Witztum JL. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation. 2008;118(6):672–677. [PubMed] 139. Simell O, Niinikoski H, Ronnemaa T, et al. Cohort Profile: The STRIP Study (Special Turku Coronary Risk Factor Intervention Project), an infancy-onset dietary and life-style intervention trial. Int J Epidemiol. 2009;38(3):650–655. [PubMed] 140. Kuklina EV, Yoon PW, Keenan NL. Prevalence of coronary heart disease risk factors and screening for high cholesterol levels among young adults, United States, 1999–2006. Ann Fam Med. 2010;8(4):327–333. [PubMed] 141. Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart Association Pediatric and Adult Nutrition Guidelines: A Scientific Statement From the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation. 2009;119(8):1161–1175. [PubMed] 142. Broyles S, Katzmarzyk PT, Srinivasan SR, et al. The pediatric obesity epidemic continues unabated in Bogalusa, Louisiana. Pediatrics. 2010;125(5):900–905. [PMC free article] [PubMed] 143. US Preventive Services Task Force Screening for obesity in children and adolescents: US Preventive Services Task Force recommendation statement. Pediatrics. 2010;125(2):361–367. [PubMed] 144. National Center for Chronic Disease Prevention and Health Promotion Healthy Youth! Available at: http://www.cdc.gov/HealthyYouth. Accessed May 16, 2011. 145. August G. Prevention and treatment of pediatric obesity: an Endocrine Society clinical practice guidelines based on expert opinion. J Clin Endocrinol Metab. 2008;93(12):4576–4599. [PubMed] 146. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38(1):46–51. [PubMed] 147. Gordon T, Kannel WB. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. Am Heart J. 1982;103(6):1031–1039. [PubMed] 148. Anderson M, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83(1):356–362. [PubMed] 149. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847. [PubMed] 150. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003. [PubMed] 151. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136–147. [PMC free article] [PubMed] 152. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC) Heart. 2007;93(2):172–176. [PMC free article] [PubMed] 153. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421. [PubMed] 154. D’Agostino RB, Sr, Grundy S, Sullivan LM, Wilson P., for the CHD Risk Prediction Group Validation of the Framingham coronary disease prediction scores. results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–187. [PubMed] 155. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) study. Circulation. 2002;105(3):310–315. [PubMed] 156. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611–619. [PubMed] 157. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation. 2008;118(22):2243–2251. [PMC free article] [PubMed] 158. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106(3):388–391. [PubMed] 160. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis. 2003;171(1):145–155. [PubMed]
161. De Backer GG. Risk factors and prevention of cardiovascular disease: a review. Dialogues Cardiovasc Med. 2008;13(2):83–99.
162. Dent THS. Predicting the risk of coronary heart disease: I. The use of conventional risk markers. Atherosclerosis. 2010;213(2):345–351. [PubMed] 163. Nasir K, Budoff MJ, Wong ND, et al. Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA) Circulation. 2007;116(6):619–626. [PubMed] 164. Parikh NI, Hwang S-J, Larson MG, et al. Parental occurrence of premature cardiovascular disease predicts increased coronary artery and abdominal aortic calcification in the Framingham Offspring and Third Generation Cohorts. Circulation. 2007;116(13):1473–1481. [PubMed] 165. Lloyd-Jones DM, Nam B-H, D’Agostino RB, Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291(18):2204–2211. [PubMed] 166. Pohjola-Sintonen S, Rissanen A, Liskola P, Luomanmäki K. Family history as a risk factor of coronary heart disease in patients under 60 years of age. Eur Heart J. 1998;19(2):235–239. [PubMed] 167. Younger JF. Family history is important in estimating coronary risk. BMJ. 2000;321(7258):448. [PMC free article] [PubMed] 168. Lloyd-Jones DM, Dyer AR, Wang R, Daviglus ML, Greenland P. Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry) Am J Cardiol. 2007;99(4):535–540. [PMC free article] [PubMed] 169. D’Agostino RB, Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–753. [PubMed] 170. De Koning JS, Klazinga NS, Koudstaal PJ, et al. Quality of care in stroke prevention: results of an audit study among general practitioners. Prev Med. 2004;38(2):129–136. [PubMed] 171. De Muylder R, Lorant V, Paulus D, et al. Obstacles to cardiovascular prevention in general practice. Acta Cardiol. 2004;59(2):119–125. [PubMed] 172. Eaton CB, Galliher JM, McBride PE, et al. Family physician’s knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. J Am Board Fam Med. 2006;19(1):46–53. [PubMed] 173. Graham IM, Stewart M, Hertog MG. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil. 2006;13(5):839–845. [PubMed] 174. Fuster V. Are predictive risk scores useful? Nat Rev Cardiol. 2009;6(8):493. [PubMed]
175. Gupta M, Kajil M, Hirjikaka S, et al. Accuracy of Cardiovascular (CV) Risk Stratification by Canadian Primary Care Physicians: Preliminary Results From the Primary Care Audit of Global Risk Management (PARADIGM) Study, Abstract 16946. Circulation. 2010;122(21 Suppl):A16946.
176. Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res. 2008;8:60. [PMC free article] [PubMed] 177. Kones R. Recent advances in the management of chronic stable angina I: Approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. Vasc Health Risk Manag. 2010;6:635–656. [PMC free article] [PubMed] 178. Madhok V, Fahey T. Cardiovascular risk estimation: important but may be inaccurate. BMJ. 2006;332(7555):1422. [PMC free article] [PubMed] 179. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol. 2003;41(9):1475–1479. [PubMed] 181. Cavanaugh-Hussey MW, Berry JD, Lloyd-Jones DM. Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment pool. Prev Med. 2008;47(6):619–623. [PMC free article] [PubMed]
182. Feeman W., Jr BGS graph predicts better than the Framingham Risk Score. J Clin Lipidol. 2010;4(3):203.
183. Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis. 2005;181(1):93–100. [PubMed] 184. Orford JL, Sesso HD, Stedman M, et al. A comparison of the Framingham and European Society of Cardiiology coronary heart disease risk prediction models in the same normative aging study. Am Heart J. 2002;144(1):95–100. [PubMed] 185. Lloyd-Jones DM. Cardiovascular risk prediction. Basic concepts, current status, and future directions. Circulation. 2010;121(15):1768–1777. [PubMed] 186. Vasan RS, Sullivan LM, Wilson PW, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med. 2005;142(6):393–402. [PubMed] 187. Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the CARDIA and MESA studies. Circulation. 2009;119(3):382–389. [PMC free article] [PubMed] 188. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115(11):1481–1501. [PubMed]
189. Rohatgi AK, Khera A. The Upcoming ATP IV Guidelines. Lipid Spin. 2010;8(4):6–9.
190. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol. 2009;25(10):567–579. [PMC free article] [PubMed] 191. Ferrario CM, Moore MA, Bestermann W, Jr, et al. COSEHC global vascular risk management quality improvement program: rationale and design. Vasc Health Risk Manag. 2010;6:1135–1145. [PMC free article] [PubMed] 192. Min JK, Shaw LJ, Devereaux RB, et al. Progostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol. 2007;50(12):1161–1170. [PubMed] 193. Johnson KM, Dowe DA, Brink JA. Traditional clinical risk assessment tools do not accurately predict coronary atherosclerotic plaque burden: a CT angiography study. Am J Roentgenol. 2009;192(1):235–243. [PubMed] 194. Johnson KM, Dowe DA. The detection of any coronary calcium outperforms Framingham Risk Score as a first step in screening for coronary atherosclerosis. Am J Roentgenol. 2010;194(5):1235–1243. [PubMed] 195. Hecht HS. The deadly double standard. The saga of screening for subclinical atherosclerosis. Am J Cardiol. 2008;101(12):1805–1807. [PubMed] 196. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk. J Am Coll Cardiol. 2009;54(14):1209–1227. [PubMed] 197. Cooney MT, Dudina A, D’Agostino R, Graham IM. Cardiovascular risk-estimation systems in primary prevention. Do they differ? Do they make a difference? Can we see into the future? Circulation. 2010;122(3):300–310. [PubMed] 198. Shah PK. Screening asymptomatic subjects for subclinical atherosclerosis. Can we, does it matter, and should we? J Am Coll Cardiol. 2010;56(2):98–105. [PubMed] 199. Lauer MS. Screening asymptomatic subjects for subclinical atherosclerosis. Not so obvious. J Am Coll Cardiol. 2010;56(2):106–108. [PubMed] 200. Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med. 2006;144(11):850–855. [PubMed] 201. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145(1):35–42. [PubMed] 202. Lloyd-Jones DM, Tian L. Predicting cardiovascular risk. So what do we do now? Arch Intern Med. 2006;166(13):1342–1344. [PubMed] 203. Dent THS. Predicting the risk of coronary heart disease. II: The role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction. Atherosclerosis. 2010;213(2):352–362. [PubMed] 204. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Eng J Med. 2006;355(25):2631–2639. [PubMed] 205. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358(20):2107–2116. [PubMed] 206. De Lemos JA, Rohatgi A. Separating the contenders from the pretenders: competitive high-throughput biomarker screening in large population-based studies. Circulation. 2010;121(22):2381–2383. [PubMed] 207. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302(1):49–57. [PMC free article] [PubMed] 208. Blankenberg S, Zeller T, Saarela O, et al. for the MORGAM Project Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: The MONICA, risk, genetics, archiving, and monograph (morgam) biomarker project. Circulation. 2010;121(22):2388–2397. [PubMed] 209. Arsenault BJ, Barter P, DeMicco DA, et al. for the TNT Study Investigators Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2011;57(1):63–69. [PubMed] 210. Berry JD, Dyer A, Carnethon M, Trian L, Greenland P, Lloyd-Jones DM. Association of traditional risk factors with cardiovascular death across 0 to 10, 10 to 20, and >20 years follow-up in men and women. Am J Cardiol. 2008;101(1):89–94. [PubMed] 211. Persell SD, Zei C, Cameron KA, Zielinski M, Lloyd-Jones DM. Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey. Arch Int Med. 2010;170(5):470–477. [PubMed] 212. Lloyd-Jones DM, Wilson PWF, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94(1):20–24. [PubMed] 213. Marma AK, Berry JD, Ning H, Persell SD, Lloyd-Jones DM. Distribution of 10-Year and Lifetime Predicted Risks for Cardiovascular Disease in US Adults: Findings From the National Health and Nutrition Examination Survey 2003 to 2006. Circ Cardiovasc Qual Outcomes. 2010;3(1):8–14. [PMC free article] [PubMed] 214. Crouse JR, III, Bots ML, Evans GW, et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. Eur J Cardiovasc Prev Rehabil. 2010;17(2):223–229. [PubMed] 215. Reiner AP, Carlson CS, Thyagarajan B, et al. Soluble P-selectin, SELP polymorphisms, and atherosclerotic risk in European-American and African-African young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb Vasc Biol. 2008;28(8):1549–1555. [PubMed] 216. Loria CM, Liu K, Lewis CE, et al. Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA study. J Am Coll Cardiol. 2007;49(20):2013–2020. [PubMed] 217. Carr JJ, Nelson JC, Wong ND, et al. Calcified coronary artery plaque measurement with cardiac ct in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) Study. Radiology. 2005;234(1):35–43. [PubMed] 218. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156(9):871–881. [PubMed] 219. Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA) Arch Intern Med. 2008;168(12):1333–1339. [PMC free article] [PubMed] 220. Pankaj GP, Raju P, Sondej E, Rodrigues E, Davis G. Use of the Joint British Society cardiovascular risk calculator before initiating statins for primary prevention in hospital medicine: experience from a large university teaching hospital. Int J Gen Med. 2010;3:379–382. [PMC free article] [PubMed] 221. Blaha M, Nasir K, DeFilippis A, et al. Association between hsCRP ≥ 2, Coronary Calcium, and Adverse Events – Implications for the JUPITER Population in the Multi-Ethnic Study of Atherosclerosis (MESA) American Heart Association Scientific Sessions. Nov 17, 2010. Abstract 12825. Summary available at: http://www.theheart.org/article/1154871.do. 222. Roth GA, Finh SD, Mokdad AH, Aekplakorn W, Hasegawae T, Lim SS. High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries. Bull World Health Organ. 2011;89(2):92–101. [PubMed] 223. Min JK, Lin FY, Gidseg DS, et al. Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the “warranty period” for remaining normal? J Am Coll Cardiol. 2010;55(11):1110–1117. [PubMed] 224. Kim KP, Einstein AJ, de González AB. Coronary artery calcification screening: estimated radiation dose and cancer risk. Arch Intern Med. 2009;169(13):1188–1194. [PMC free article] [PubMed] 225. Smith-Bindman R, Lipson J, Marcus R, et al. Dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169(22):2078–2086. [PubMed] 226. Redberg RF. Cancer risks and radiation exposure from computed tomographic scans: how can we be sure that the benefits outweigh the risks? Arch Intern Med. 2009;169(22):2049–2050. [PubMed] 227. Nambi V, Ballantyne CM. “Risky business”: ten years is not a lifetime. Circulation. 2009;119(3):362–364. [PubMed]
228. Nambi V, Chambless L, Folsom AR, et al. Are all patients considered “low risk” for coronary heart disease really low risk? An analysis from the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2008;118(Suppl 2):S1125.
229. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–1080. [PubMed] 230. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–1565. [PubMed] 231. Artinian NT, Fletcher GJ, Mozaffarian D, et al. on behalf of the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation. 2010;122(4):406–441. [PubMed] 232. Yancy CW. Transformation of cardiovascular health: presidential address at the American Heart Association 2009 scientific sessions. Circulation. 2010;121(25):2773–2776. [PubMed] 233. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment. Lancet. 2005;366(9493):1267–1278. [PubMed] 234. Saely CH, Drexel H, Huber K. High-dose statin therapy for high-risk patients. Herz (Hochdosierte Statintherapie für kardiovaskuläre Risikopatienten) 2010;35(7):497–502. [PubMed] 235. Cheung BM, Lam KS. Is intensive LDL-cholesterol lowering beneficial and safe? Lancet. 2010;376(9753):1622–1624. [PubMed] 237. Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation. 2001;103(4):604–616. [PubMed] 238. Nicholls SJ, Hsu A, Wolski K, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55(21):2399–2407. [PubMed] 239. DeMaria AN, Narula J, Mahmud E, Tsimikas S. Imaging vulnerable plaque by ultrasound. J Am Coll Cardiol. 2006;47(Suppl 8):C32–C39. [PubMed]
240. Maehara A, Mintz GS, Cristea E, et al. Even after percutaneous coronary intervention of angiographically significant lesions, IVUS-defined high-grade stenoses are common. A baseline IVUS analysis from The Prospect Trial. J Am Coll Cardiol. 2010;55:A204.E1921.
241. Briguori C, Tobis J, Nishida T, et al. Discrepancy between angiography and intravascular ultrasound when analysing small coronary arteries. Eur Heart J. 2002;23(3):247–254. [PubMed] 242. Ballantyne CM, Raichlen JS, Nicholls S, et al. ASTEROID Investigators Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117(19):2458–2466. [PubMed] 243. Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI. Intracoronary optical coherence tomography: a comprehensive review: clinical and research applications. JACC Cardiovasc Interv. 2009;2(11):1035–1046. [PubMed] 244. Kubo T, Imanishi T, Kashiwagi M, et al. Multiple coronary lesion instability in patients with acute myocardial infarction as determined by optical coherence tomography. Am J Cardiol. 2010;105(3):318–322. [PubMed] 245. Yamamoto T, Lu C, Ryan RO. A Two-step binding model of PCSK9 Interaction with the low density lipoprotein receptor. J Biol Chem. 2011;286(7):5464–5470. [PubMed] 246. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Suppl):S172–S177. [PubMed] 247. Cohen JC, Boerwinkle E, Mosley TH, Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–1272. [PubMed] 248. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjærg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010;55(25):2833–2842. [PubMed] 249. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156. [PubMed]
250. Myocardial Infarction Genetics Consortium Proprotein convertase subtilisin/kexin type 9 (PCSK9) missense variant is reproducibly associated with early-onset myocardial infarction in >1500 cases and 1500 controls (abstr) Circulation. 2007;116:II806.
251. Steinberg D. Earlier intervention in the management of hypercholesterolemia: what are we waiting for? J Am Coll Cardiol. 2010;56(8):627–629. [PubMed] 252. Kones R. Recent advances in the management of chronic stable angina. II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag. 2010;6:749–774. [PMC free article] [PubMed] 253. Domanski MJ. Primary prevention of coronary artery disease. N Engl J Med. 2007;357(15):1543–1545. [PubMed] 254. Redberg R, Benjamin EJ, Bittner V, et al. ACCF/AHA 2009 Performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women’s Health Research. J Am Coll Cardiol. 2009;54(14):1364–1405. [PubMed] 255. Forrester JS. Redefining normal low-density lipoprotein cholesterol: a strategy to unseat coronary disease as the nation’s leading killer. J Am Coll Cardiol. 2010;56(8):630–636. [PubMed] 256. DeMazumder D, Hasan RK, Blumenthal RS, Michos ED, Jones S. Should statin therapy be allocated on the basis of global risk or on the basis of randomized trial evidence? Am J Cardiol. 2010;106(6):905–909. [PubMed] 257. Nambi V, Ballantyne CM. Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. Curr Atheroscler Rep. 2005;7(1):22–28. [PubMed] 258. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol. 2003;92(4B):17K–22K. [PubMed] 259. Mähönen MS, McElduff P, Dobson AJ, Kuulasmaa KA, Evans AE., for the WHO MONICA Project Current smoking and the risk of non-fatal myocardial infarction in the WHO MONICA Project populations. Tob Control. 2004;13(3):244–250. [PMC free article] [PubMed] 260. Bakhru A, Erlinger TP. Smoking cessation and cardiovasacular disease risk factors: Results from the third National Health and Nutrition Examination Survey. PLoS Med. 2005;2(6):e160. [PMC free article] [PubMed] 261. Yusuf S, Lonn E, Bosch J. Lipid lowering for primary prevention. Lancet. 2009;373(9670):1152–1155. [PubMed] 262. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26(1):60–69. [PubMed] 263. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46(1):156–161. [PubMed] 264. Yeh RW, Sidney S, Chandra M, Sorel M, Selby J, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362(23):2155–2165. [PubMed] 265. Brown JR, O’Connor GT. Coronary heart disease and prevention in the United States. N Eng J Med. 2010;362(23):2150–2153. [PubMed] 266. Garcia-Garcia HM, Costa MA, Serruys PW. Imaging of coronary atherosclerosis: intravascular ultrasound. Eur Heart J. 2010;31(20):2456–2469. [PubMed] 267. Sipahi I, Nicholls SJ, Tuzcu EM, Nissen SE. Coronary atherosclerosis can regress with very intensive statin therapy. Cleve Clin J Med. 2006;73(10):937–944. [PubMed] 268. Mack WJ, Xiang M, Selzer RH, Hodis HN. Serial quantitative coronary angiography and coronary events. Am Heart J. 2000;139(6):993–999. [PubMed] 269. Buchwald H, Matts JP, Fitch LL, et al. for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268(11):1429–1433. [PubMed] 270. Petronio AS, Amoroso G, Limbruno U, et al. Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. Am Heart J. 2005;149(3):520–526. [PubMed] 271. Tani S, Watanabe I, Anazawa T, et al. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol. 2005;96(8):1089–1094. [PubMed] 272. Takashima H, Ozaki Y, Yasukawa T, et al. Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque. Circ J. 2007;71(11):1678–1684. [PubMed] 273. Takayama T, Hiro T, Yamagishi M, et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS) Circ J. 2009;73(11):2110–2117. [PubMed] 274. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intra-vascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study) J Am Coll Cardiol. 2009;54(4):293–302. [PubMed] 275. Hirayama A, Saito S, Ueda Y, et al. Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy. Circ J. 2009;73(4):718–725. [PubMed] 276. Inoue K, Motoyama S, Sarai M, et al. Serial coronary CT angiography–verified changes in plaque characteristics as an end point: evaluation of effect of statin intervention. JACC Cardiovasc Imaging. 2010;3(7):691–698. [PubMed] 277. Stone GW, Maehara A, Lansky AJ, et al. for the PROSPECT Investigators A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–235. [PubMed] 278. Bayturan O, Kapadia S, Nicholls SJ, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010;55(24):2736–2742. [PubMed] 279. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–1182. [PubMed]
280. Van der Zijl NJ, Muskiet HA, Tushuizen ME, et al. C-reactive protein mediates the association of liver fat and carotid intima–media thickness in healthy men and men with the metabolic syndrome and/or uncomplicated type 2 diabetes. Diab Met Syndr Clin Res Rev. 2010;4(3):160–164.
281. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl 5):v1–v52. [PMC free article] [PubMed] 282. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252. [PubMed] 285. Royal College of General Practitioners London: RCGP; 2008. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE Clinical guideline 67. Reissued March, 2010. Available at: http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11982. Accessed March 24, 2011. [PubMed] 286. Grundy SM, Cleeman JI, Merz CN, et al. The Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110(2):227–239. [PubMed] 287. Beri A, Contractor T, Khasnis A, Thakur R. Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect? Am J Cardiovasc Drugs. 2010;10(3):155–164. [PubMed] 288. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):1–160. [PubMed] 289. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(21):2307–2313. [PubMed] 290. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22):1769–1781. [PubMed] 291. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. [PMC free article] [PubMed] 292. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024–1031. [PubMed] 293. Pasternak RC, Smith SC, Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567–572. [PubMed] 294. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute. American College of Cardiology Foundation. American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239. [PubMed] 295. Bukkapatnam RN, Gabler NB, Lewis WR. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. Prev Cardiol. 2010;13(2):84–90. [PubMed] 296. Nakamura H, Arakawa K, Itakura H, et al. MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet. 2006;368(9542):1155–1163. [PubMed] 297. Nakamura H. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atheroscler Suppl. 2007;8(2):13–17. [PubMed] 298. Taylor F, Ward K, Moore THM, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1:CD004816. [PubMed] 299. Gotto AM. Improving lipid goal attainment. is it enough? Circulation. 2009;120(1):3–5. [PubMed] 300. Pletcher MJ, Hulley SB. Statin therapy in young adults: ready for prime time? J Am Coll Cardiol. 2010;56(8):637–640. [PubMed] 301. Cooper A, O’Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ. 2008;336(7655):1246–1248. [PMC free article] [PubMed] 302. Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate-and low-cardiovascular-risk individuals for statin therapy. Circulation. 2010;122(15):1478–1487. [PubMed] 303. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. Molecular basis of statin-associated myopathy. Atherosclerosis. 2009;202(1):18–28. [PubMed] 304. Mas E, Mori TA. Coenzyme Q10 and statin myalgia: what is the evidence? Curr Atheroscler Rep. 2010;12(6):407–413. [PubMed] 305. Vandenberg BF, Robinson J. Management of the patient with statin intolerance. Curr Atheroscler Rep. 2010;12(1):48–57. [PubMed] 306. Thompson PD, Clarkson PM, Rosenson RS., National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel An assessment of statin safety by muscle experts. Am J Cardiol. 2006;97(8A):69C–76C. [PubMed] 307. Deedwania P, Stone PH, Bairey Merz CN. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE) Circulation. 2007;115(6):700–707. [PubMed] 308. Gotto AM., Jr Statin therapy and the elderly: SAGE Advice? Circulation. 2007;115(6):681–683. [PubMed]
309. Golomb B. Statin adverse effects: implications for the elderly. Geriatric Times. 2004;5(4):18–20.
310. Nichols GA, Nag S, Chan W. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am Heart J. 2007;154(3):554–560. [PubMed] 311. Maroo BP, Lavie CJ, Milani RV. Efficacy and safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol. 2008;17(2):92–100. [PubMed] 312. Wenger NK, Lewis SJ. Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients. Curr Gerontol Geriatr Res. 2010;915296 [PMC free article] [PubMed] 313. Long SB, Blaha MJ, Blumenthal RS, Michos ED. Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. Clin Interv Aging. 2011;6:27–35. [PMC free article] [PubMed] 314. Pletcher MJ, Coxson PG. Does age modify effectiveness of statin therapy in coronary artery disease? Ann Intern Med. 2010;152(12):825. [PubMed] 315. Lewington S, Whitlock G, Clarke R, et al. Prospective Studies Collaboration Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–1839. [PubMed] 316. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150(4):243–254. [PubMed] 317. Hayward RA. Does age modify effectiveness of statin therapy in coronary artery disease? Ann Intern Med. 2010;152(12):825–826. [PubMed] 318. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152(8):488–496. [PMC free article] [PubMed] 319. Zieman SJ, Ouyang P. Statins for primary prevention in older adults: who is high risk, who is old, and what denotes primary prevention? Ann Int Med. 2010;152(8):528–530. [PubMed] 320. Jaffer FA, O’Donnell CJ, Larson MG, et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22(5):849–854. [PubMed] 321. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504. [PubMed] 322. Ray KK, Cannon, Cairns R, et al. PROVE IT-TIMI 22 Investigators Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol. 2005;46(8):1417–1424. [PubMed] 323. Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724–730. [PubMed] 324. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002;105(12):1424–1428. [PubMed] 325. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301–1310. [PubMed] 326. Arsenault BJ, Rana JS, Stroes ESG, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non– high density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2010;55(1):35–41. [PubMed] 327. Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106(6):757–763. [PubMed] 328. Núñez-Cortés JM, Juan Montoya JP-B, Salas XP, et al. Estudio REALIST (REsiduAl risk, LIpids and Standard Therapies): Un análisis del Riesgo Residual dependiente del perfil lipídico en el síndrome coronario agudo. Endocrinol Nutr. 2011;58(1):38–47. [PubMed]
329. Neil CE, Nicklas TA. Relationship Between Diet/Physical Activity and Health. Am J Lifestyle Med. 2007;1(6):457–481.
330. Stevens J, McClain JE, Truesdale JP. Commentary: Obesity claims and controversies. Int J Epidemiol. 2006;35(1):77–78. [PubMed] 331. Chamberlain J, Francis S, Brookes Z, et al. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS ONE. 2009;4(4):e5073. [PMC free article] [PubMed] 332. Lamon BD, Hajjar DP. Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol. 2008;173(5):1253–1264. [PubMed] 333. McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med. 2007;167(7):642–648. [PubMed] 334. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;89(6):2563–2568. [PubMed] 335. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89(6):2583–2589. [PubMed] 336. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–2556. [PubMed] 337. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr. 2010;91(1):258S–261S. [PubMed] 338. Hajer GR, van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29(24):2959–2971. [PubMed] 339. Boden G. Endoplasmic reticulum stress: another link between obesity and insulin resistance/inflammation? Diabetes. 2009;58(3):518–519. [PMC free article] [PubMed] 340. Rasouli N, Kern PA. Adipocytokines and the Metabolic Complications of Obesity. J Clin Endocrinol Metab. 2008;93(11 Supp1):s64–s73. [PubMed] 341. Zhang H, Zhang C. Adipose “talks’ to distant organs to regulate insulin sensitivity and vascular function. Obesity. 2010;18(11):2071–2076. [PMC free article] [PubMed] 342. Berman DS, Cheng VY, Dey D. Not all body fat weighs equally in the acceleration of coronary artery disease. J Am Coll Cardiol Img. 2010;3(9):918–920. [PMC free article] [PubMed] 343. Ohashi N, Yamamoto H, Horiguchi J, et al. Association between visceral adipose tissue area and coronary plaque morphology assessed by ct angiography. JACC Cardiovasc Imaging. 2010;3(9):908–917. [PubMed] 344. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol 50 mg/dl with rosuvastatin. J Am Coll Cardiol. 2011;57(16):1666–1675. [PubMed] 345. McMurray JJ, Holman RR, Haffner SM, et al. The NAVIGATOR Study Group Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–1490. [PubMed] 346. Holman RR, Haffner SM, McMurray JJ, et al. The NAVIGATOR Study Group Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1463–1476. [PubMed] 347. Ginsberg HN, Elam MB, Lovato LC, et al. for The ACCORD Study Group Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362(17):1563–1574. [PMC free article] [PubMed] 348. Nilsson PM. ACCORD and Risk-Factor Control in Type 2 Diabetes. N Eng J Med. 2010;362(17):1628–1630. [PubMed] 349. Nicholls SJ, Lundman P, Tardif J-C. Diabetic dyslipidemia: extending the target beyond LDL cholesterol. Eur J Cardiovasc Prev Rehabil. 2010;17(suppl 1):s20–s24. [PubMed]
350. Hermans MP, Fruchaart J-C. Reducing residual vascular risk in patients with atherogenic dyslipidemia: Where do we go from here? Clin Lipidol. 2010;5(6):811–826.
351. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8–15. [PubMed] 352. Nicholls SJ, Tuzcu EM, Sipaghi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297(5):499–508. [PubMed] 353. Brown B, Zhao X, Cheung M. Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence. J Clin Lipidol. 2007;1(1):88–94. [PMC free article] [PubMed] 354. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J. 2008;156(1):112–119. [PubMed] 355. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157(1):111–117.e2. [PubMed] 356. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104(10):1108–1113. [PubMed] 357. Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000. [PMC free article] [PubMed] 358. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009;338:b92. [PMC free article] [PubMed] 359. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation. 2000;101(5):477–484. [PubMed] 360. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) Am J Cardiol. 2003;92(2):152–160. [PubMed] 361. Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuva-statin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004;26(9):1388–1399. [PubMed] 362. Negi S, Ballantyne CM. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. J Clin Lipidol. 2010;4(5):365–370. [PubMed]
364. Saleem TSM, Rani PVS, Gauthaman K. High-density lipoproteins: a novel therapeutic target for cardiovascular disease. Res Reports Clin Cardiol. 2011;2:1–6.
365. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117(3):746–756. [PMC free article] [PubMed] 366. Greene DJ, Skeggs JW, Morton RE. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI) J Biol Chem. 2001;276(7):4804–4811. [PubMed] 367. Saddar S, Mineo C, Shaul PW. Signaling by the high-affinity hdl receptor scavenger receptor B type I. Arterioscler Thromb Vasc Biol. 2010;30(2):144–150. [PubMed] 368. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8(4):222–232. [PubMed] 369. Brewer HB, Jr, Santamarina-Fojo S. New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am J Cardiol. 2003;91(7A):3E–11E. [PubMed] 370. Navab M, Shechter I, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM. structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol. 2010;30(2):164–168. [PMC free article] [PubMed] 371. Masson D, Jiang XC, Lagrost L, Tall AR. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res. 2009;50(Suppl):S201–S206. [PubMed] 372. Khera AV, Cuchel M, Margarita de la Llera-Moya, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127–135. [PMC free article] [PubMed] 373. Heinecke J. HDL and Cardiovascular-Disease risk – time for a new approach? N Engl J Med. 2011;364(2):170–171. [PubMed] 374. Rosenblat M, Aviram M. Paraoxonases role in the prevention of cardiovascular diseases. Biofactors. 2009;35(1):98–104. [PubMed] 375. Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol. 2004;15(3):261–267. [PubMed] 376. Andersen RV, Wittrup HH, Tybjaerg-Hansen A, Steffensen R, Schnohr P, Nordestgaard BG. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol. 2003;41(11):1972–1982. [PubMed] 377. Corsetti JP, Zareba W, Moss AJ, Rainwater DL, Sparks CE. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis. 2006;187(1):191–197. [PubMed] 378. DeGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51(1):49–55. [PubMed] 379. van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk. J Am Coll Cardiol. 2008;51(6):634–642. [PubMed] 380. Corsetti JP, Gansevoort RT, Sparks CE, Dullaart RPF. HDL inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest. 2010;40(6):483–489. [PubMed] 381. Dullaart RPF. Increased coronary heart disease risk determined by high high-density lipoprotein cholesterol and c-reactive protein: modulation by variation in the CETP gene. Arterioscler Thromb Vasc Biol. 2010;30(8):1502–1503. [PubMed] 382. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. [PubMed] 383. Davidson WS, Silva RAGD, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol. 2009;29(6):870–876. [PMC free article] [PubMed] 384. Yancey PG, Bortnick AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;123(5):712–719. [PubMed] 385. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med. 2006;3(3):144–153. [PubMed] 386. Zheng L, Nukuna B, Brennan M-L, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114(4):529–541. [PMC free article] [PubMed] 387. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102(16):1886–1892. [PubMed] 388. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol. 2010;23(3):447–454. [PMC free article] [PubMed] 389. Norata GD, Pirillo A, Catapano AL. Modified HDL: biological and physiopathological consequences. Nutr Metabol Cardiovasc Dis. 2006;16(5):371–386. [PubMed] 390. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45(7):1169–1196. [PubMed] 391. Esteve E, Ricart W, Fernandez-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 2005;24(1):16–31. [PubMed] 392. Navab M, Anantharamaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45(6):993–1007. [PubMed] 393. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108(22):2751–2756. [PubMed] 394. Briffa TG, Hobbs MS, Tonkin A, et al. Population trends of recurrent coronary heart disease event rates remain high. Circ Cardiovasc Qual Outcomes. 2010;4(1):107–113. [PubMed] 396. Ansell BJ. Targeting the anti-inflammatory effects of high-density lipoprotein. Am J Cardiol. 2007;100(11A):n3–9. [PubMed] 397. Green PS, Vaisar T, Pennathur S, et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation. 2008;118(12):1259–1267. [PMC free article] [PubMed] 398. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121(1):110–122. [PubMed] 399. Heslop CL, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J Am Coll Cardiol. 2010;55(11):1102–1109. [PubMed] 400. Singh U, Devaraj S, Jialal I. C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem. 2009;55(2):361–364. [PMC free article] [PubMed] 401. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003;36(6):421–429. [PubMed] 402. Xiao C, Watanabe T, Zhang Y, et al. Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Circ Res. 2008;103(2):159–166. [PubMed] 404. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004;89(10):4963–4971. [PubMed] 405. Nobecourt E, Jacqueminet S, Hansel B, et al. Defective antioxidative activity of small, dense HDL particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycemia. Diabetologia. 2005;48(3):529–38. [PubMed] 406. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58(3):342–374. [PubMed] 407. Getz GS, Reardon CA. High-density lipoprotein function in regulating insulin secretion: possible relevance to metabolic syndrome. Arterioscler Thromb Vasc Biol. 2010;30(8):1497–1499. [PMC free article] [PubMed] 408. Oksjoki R, Kovanen PT, Pentikainen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol. 2003;14(5):477–482. [PubMed] 409. Heinecke JW. The protein cargo of HDL: Implications for vascular wall biology and therapeutics. J Clin Lipidol. 2010;4(5):371–375. [PMC free article] [PubMed] 410. McGillicuddy FC, de la Llera MM, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009;119(8):1135–1145. [PubMed] 411. Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J Lipid Res. 2003;44(9):1728–1736. [PubMed] 412. Annema W, Nijstad N, Tolle M, et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2) J Lipid Res. 2010;51(4):743–754. [PubMed] 413. Inouye M, Silander K, Hamalainen E, et al. An immune response network associated with blood lipid levels. PLoS Genet. 2010;6(9):e1001113. [PMC free article] [PubMed] 414. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res. 2010;51(8):2032–2057. [PubMed] 415. Corsetti JP, Ryan D, Rainwater DL, Moss AJ, Zareba W, Sparks CE. Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels. Arterioscler Thromb Vasc Biol. 2010;30(8):1657–1664. [PMC free article] [PubMed] 416. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res. 2001;42(8):1308–1317. [PubMed] 417. Karthikeyan G, Teo KK, Islam S, et al. Lipid profile, plastma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART study. J Am Coll Cardiol. 2009;53(3):244–253. [PubMed] 418. Dodani S, Kaur R, Reddy S, Reed GL, Navab M, George V. Can dysfunctional HDL explain high coronary artery disease risk in south Asians? Int J Cardiol. 2008;129(1):125–132. [PubMed]
419. Dodani S. Can conventional risk factors explain excess coronary artery disease risk in south asians: dyslipidemias and dysfunctional high density lipoprotein (HDL) Open Epidemiol J. 2009;2:55–62.
420. Das UN. A defect in Δ6 and Δ5 desaturases may be a factor in the initiation and progression of insulin resistance, the metabolic syndrome and ischemic heart disease in South Asians. Lipids Health Dis. 2010;9:130. [PMC free article] [PubMed] 421. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31(2):149–164. [PMC free article] [PubMed] 422. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. J Lipid Res. 2009;50(Suppl):S195–S200. [PubMed] 423. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis. 2010;208(1):3–9. [PubMed] 424. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol. 2010;55(13):1283–1299. [PubMed] 425. Dodani S, Grice DG, Joshi S. Is HDL function as important as HDL quantity in the coronary artery disease risk assessment? J Clin Lipidol. 2009;3(2):70–77. [PubMed] 426. Alla VM, Manu K, Mooss A. Targeting residual risk: the rationale for the use of non-HDL cholesterol. Southern Med J. 2010;103(5):434–437. [PubMed] 427. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–2122. [PubMed]
428. Toth P. Torcetrapib and atherosclerosis: what happened and where do we go from here? Future Lipidol. 2007;2(3):277–284.
429. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304–1316. [PubMed] 430. Cannon CP, Dansky HM, Davidson M, et al. Design of the DEFINE trial: Determining the efficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009;158(4):513–519e3. [PubMed] 431. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Eng J Med. 2010;363(25):2406–2415. [PubMed] 432. Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharm Therap. 2008;84(6):679–683. [PubMed] 433. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157(2):352–360e2. [PubMed] 434. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370(9603):1907–1914. [PubMed] 435. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010;30(7):1430–1438. [PMC free article] [PubMed] 436. Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-i synthesis in statin-treated patients with stable coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2011;57(9):1111–1119. [PubMed] 437. Davidson MH. Apolipoprotein A-I therapy: promise, challenges, and disappointment. J Am Coll Cardiol. 2011;57(9):1120–1121. [PubMed] 438. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol. 2006;17(6):631–636. [PubMed] 439. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):2113–2122. [PubMed] 442. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298(7):776–785. [PubMed] 443. Parish S, Peto R, Palmer A, et al. The joint effects of apolipoprotein B, apolipoprotein A 1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J. 2009;30(17):2137–2146. [PMC free article] [PubMed] 444. Lewington S, Whitlock G, Clarke, et al. for Prospective Studies Collaboration Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet. 2007;370(6902):1829–1839. [PubMed] 445. Kastelein JJP, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117(23):3002–3009. [PubMed] 446. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11):1413–1419. [PubMed] 447. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112(22):3375–3383. [PubMed] 448. El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49(5):547–553. [PubMed] 449. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipid and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119(7):931–939. [PMC free article] [PubMed] 450. Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle number. A prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006;113(1):20–29. [PubMed] 451. Otvos JD, Collins D, Freedman SD, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113(12):1556–1563. [PubMed] 452. Hsia J, Otvos JD, Rossouw JE, et al. for the Women’s Health Initiative Research Group Lipoprotein particle concentrations may explain the absence of coronary protection in the women’s health initiative hormone trials. Arterioscler Thromb Vasc Biol. 2008;28(9):1666–1671. [PMC free article] [PubMed] 453. Adiels M, Borén J, Caslake MJ, et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2005;25(8):1697–1703. [PubMed] 454. Brunzell JD, Davidson M, Furberg CD, et al. lipoprotein management in patients with cardiometabolic risk. consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51(15):1512–1524. [PubMed] 455. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices. Clin Chem. 2009;55(3):407–419. [PubMed] 456. Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis. 2007;192(1):211–217. [PubMed] 457. Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus. Diabet Med. 2011 Jan 18; doi: 10.1111/j.1464-5491.2011.03240.x. [Epub ahead of print]. [PubMed] [Cross Ref] 458. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on low-density and high-density lipoprotein particle concentrations in patients with the metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care. 2009;32(6):1087–1091. [PMC free article] [PubMed]
459. Dayspring T, Dall T, Abuhajir M. Moving beyond LDL-C: incorporating lipoprotein particle numbers and geometric parameters to improve clinical outcomes. Research Reports Clin Cardiol. 2010;1:1–10.
460. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98(10):1363–1368. [PubMed] 461. Takahashi O, Glasziou PP, Perera R, et al. Lipid re-screening: what is the best measure and interval? Heart. 2010;96(6):448–452. [PubMed] 462. Glasziou PP, Irwig L, Heritier S, et al. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med. 2008;148(9):656–661. [PubMed] 463. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224–233. [PubMed] 464. Nordestgaard BG, Chapman MJ, Ray K, et al. for the European Atherosclerosis Society Consensus Panel Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853. [PMC free article] [PubMed] 465. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten country panel. J Intern Med. 2006;259(3):247–258. [PubMed] 466. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham offspring study – implications for LDL management. J Clin Lipidol. 2007;1(6):583–592. [PMC free article] [PubMed] 467. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874. [PubMed] 468. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002;252(4):283–294. [PubMed] 469. Esposito K, Giugliano D. Diet and inflammation: a link to metabolic and cardiovascular diseases. Eur Heart J. 2006;27(1):15–20. [PubMed] 470. Ross R. The pathogenesis of atherosclerosis-a perspective for the 1990s. Nature. 1993;362(6423):801–809. [PubMed] 471. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74(2):213–220. [PubMed] 472. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91(4):281–291. [PubMed] 473. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95. [PubMed] 474. Libby P, Nahrendorf M, Pittet MJ, Swirski FK. Diversity of denizens of the atherosclerotic plaque: not all monocytes are created equal. Circulation. 2008;117(25):3168–3170. [PubMed] 475. Selvin E, Paynter NP, Erlinger TP. The effect of weight loss on c-reactive protein: a systematic review. Arch Intern Med. 2007;167(1):31–39. [PubMed] 476. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;(2):237–242. [PubMed] 477. Ridker PM, Buring JE, Cook NR, Rifai N. C-Reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391–397. [PubMed] 478. Jialal I. The role of the laboratory in the diagnosis of the metabolic syndrome. Am J Clin Pathol. 2009;132(2):161–162. [PubMed] 479. Pitsavos C, Panagiotakos DB, Tzima N, et al. Diet, exercise, and C-reactive protein levels in people with abdominal obesity: the ATTICA Epidemiological Study. Angiology. 2007;58(2):225–233. [PubMed] 480. Esmaillzadah A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome. Am J Clin Nutr. 2006;84(6):1489–2497. [PubMed] 481. Micallef MA, Munro IA, Garg ML. An inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individuals. Eur J Clin Nutr. 2009;63(9):1154–1156. [PubMed] 482. Imhof A, Froehlich M, Brenner H, et al. Effect of alcohol consumption on systemic markers of inflammation. Lancet. 2001;357(9258):763–767. [PubMed] 483. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation. 2003;107(3):443–447. [PubMed] 484. Greenfield JR, Samaras K, Jenkins AB, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation. 2004;109(24):3022–3028. [PubMed] 485. Jiao P, Xu H. Adipose inflammation: cause or consequence of obesity-related insulin resistance. Diabetes Metab Syndr Obes. 2008;1:25–31. [PMC free article] [PubMed] 486. Schuster DP. Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation. Diabetes Metab Syndr Obes. 2010;3:253–262. [PMC free article] [PubMed] 487. Wang A, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010;535918 [PMC free article] [PubMed] 488. Lin Xu L, Jiang CQ, Lam TH, et al. The metabolic syndrome is associated with subclinical atherosclerosis independent of insulin resistance: the Guangzhou Biobank Cohort Study-CVD. Clin Endocrinol (Oxf) 2010;73(2):181–188. [PubMed] 489. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289(14):1799–1804. [PubMed] 490. Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets. 2003;4(6):487–492. [PubMed] 491. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004;292(12):1440–1446. [PubMed] 492. Belalcazar LM, Reboussin DM, Haffner SM, et al. for The Look AHEAD Research Group A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change. Diabetes Care. 2010;33(11):2297–2303. [PMC free article] [PubMed] 493. Wassel CL, Barrett-Connor E, Laughlin G. Association of circulating C-reactive protein and interleukin-6 with longevity into the 80s and 90s: The Rancho Bernardo Study. J Clin Endocrinol Metab. 2010;95(10):4748–4755. [PubMed] 494. Kravitz BA, Corrada MM, Kawas CH. High levels of serum C-reactive protein are associated with greater risk of all-cause mortality, but not dementia, in the oldest-old: results from the 90+ Study. J Am Ger Soc. 2009;57(4):641–646. [PMC free article] [PubMed] 495. Currie CJ, Poole CD, Conway P. Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality. Heart. 2008;94(4):457–462. [PubMed] 496. Marsik C, Kazemi-Shirazi L, Schickbauer T, et al. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem. 2008;54(2):343–349. [PubMed] 497. Kaptoge S, Di Angelantonio E, Lowe G, et al. The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–140. [PMC free article] [PubMed] 498. Kangasniemi O-P, Biancari F, Luukkonen J, et al. Preoperative C-reactive protein is predictive of long-term outcome after coronary artery bypass surgery. Eur J Cardiothorac Surg. 2006;29(6):983–985. [PubMed] 499. Ishii H, Toriyama T, Aoyama T, et al. Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimuseluting stents in patients on hemodialysis. Circ Cardiovasc Interv. 2009;2(6):513–518. [PubMed] 500. Otake H, Shite J, Shinke T, et al. Relation between plasma adiponectin, high sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome. Am J Cardiol. 2008;101(1):1–7. [PubMed] 501. Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114(4):281–288. [PubMed] 502. Nissen SE. Does intensive statin therapy lower mortality and cardiovascular event risk in patients with acute coronary syndrome? Nat Clin Pract Cardiovasc Med. 2005;2(1):10–11. [PubMed] 503. Radjesh J, Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ESG, Kastelein JJP. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J. 2010;31(17):2087–2091. [PubMed] 504. Weber M, Bhatt DL, Brennan DM, et al. for the CHARISMA Investigators High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart. 2011;97(8):626–631. [PubMed] 505. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6(7):508–519. [PubMed] 506. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54(1):24–38. [PubMed] 507. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–820. [PubMed] 508. Chang M-K, Binder CH, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002;99(20):13043–13048. [PubMed] 509. Bu DX, Lichtman AH. T cells and blood vessels. costimulation turns up the pressure. Circulation. 2010;122(24):2495–2498. [PMC free article] [PubMed] 510. Lumeng CN, Maillard I, Saltiel AR. T-ing up inflammation in fat. Nat Med. 2009;15(8):846–847. [PubMed] 511. Vinh A, Chen W, Blinder Y, et al. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation. 2010;122(24):2529–2537. [PMC free article] [PubMed] 512. Rizzo M, Corrado E, Coppola G, et al. The predictive role of C-reactive protein in patients with hypertension and subclinical atherosclerosis. Intern Med J. 2009;39(8):539–545. [PubMed]
513. Novo S, Russo R, Toia P, et al. Subclinical atherosclerosis, inflammation and events. Journal ESC Council Clin Cardiol. 2011;19(16):1–3.
514. Van Royen N, Piek JJ, Schaper W, Fulton WF. A critical review of clinical arteriogenesis research. J Am Coll Cardiol. 2009;55(1):17–25. [PubMed] 515. De Groot D, Hoefer IE, Grundmann S, et al. Arteriogenesis requires toll-like receptor 2 and 4 expression in bone-marrow derived cells. J Mol Cell Cardiol. 2011;50(1):25–32. [PubMed] 516. Monaco C. Innate immunity meets arteriogenesis: The versatility of toll-like receptors. J Mol Cell Cardiol. 2011;50(1):9–12. [PubMed] 517. De Lorgeril M, Salen P, Martin JL, Monjaud I, Boucher P, Mamelle N. Mediterranean dietary pattern in the randomized trial: prolonged survival and possible reduced cancer rate. Arch Int Med. 1998;158(11):1181–1187. [PubMed] 518. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction – final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779–785. [PubMed] 519. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282(21):2012–2018. [PubMed] 520. De Lorgeril M, Salen P. Diet as preventive medicine in cardiology. Curr Opin Cardiol. 2000;15(5):364–370. [PubMed] 521. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292(12):1433–1439. [PubMed] 522. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med. 2003;348(26):2599–2608. [PubMed] 523. Mitrou PN, Kipnis V, Thiébaut ACM, et al. Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med. 2007;167(22):2461–2468. [PubMed] 524. Crowe FL, Roddam AW, Key TJ., European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart Study Collaborators Fruit and vegetable intake and mortality from ischaemic heart disease: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study. Eur Heart J. 2011;32(10):1235–1243. [PMC free article] [PubMed] 525. Capewell S, Lloyd-Jones DM. Optimal cardiovascular prevention strategies for the 21st century. JAMA. 2010;304(18):2057–2058. [PubMed] 526. Wilson JT, Lloyd-Jones DM. Biomarkers for coronary heart disease clinical risk prediction: A critical appraisal. Prev Cardiol. 2010;13(4):160–165. [PubMed] 527. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53(4):316–322. [PubMed] 528. Blaha M, Blumenthal R, Brinton E, Jacobson T., On behalf of the National Lipid Association Taskforce on Non-HDL Cholesterol The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol. 2008;2(4):267–273. [PubMed] 529. Robinson JG. Are you targeting non-high-density lipoprotein cholesterol? J Am Coll Cardiol. 2010;55(1):42–44. [PubMed]
530. Wilkins JT, Lloyd-Jones DM. Short-term versus lifetime risk assessment for cardiovascular disease: Pros, cons, and clinical implications. Curr Cardiovasc Risk Rep. 2009;3(2):144–149.
531. Pencina MJ, D’Agostino RB, Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119(24):3078–3084. [PMC free article] [PubMed] 532. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207. [PubMed] 533. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertension. 2009;27(11):2121–2158. [PubMed] 534. Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk >5% or Framingham risk >20%: Post hoc analyses of the JUPITER trial requested by the European health authorities. Eur Heart J. 2011;32(1):75–83. [PMC free article] [PubMed] 535. Choudhry NK, Patrick AR, Glynn RJ, Avorn J. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardiol. 2011;57(7):784–791. [PubMed] 536. Hlatky M. The cost-effectiveness of rosuvastatin therapy: JUPITER (Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) J Am Coll Cardiol. 2011;57(7):792–793. [PubMed] 537. De Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med. 2010;170(12):1032–1036. [PubMed]
538. Carrera-Bastos P, Fontes M, O’Keefe JH, Lindeberg S, Cordain L. The Western Diet and lifestyle and diseases of civilization. Res Reports Clin Cardiol. 2011;2:15–35.
539. Mookadam F, Moustafa SE, Lester SJ, Warsame T. Subclinical atherosclerosis: Evolving role of carotid intima-media thickness. Prev Cardiol. 2010;13(4):186–197. [PubMed] 540. Liviakis L, Pogue B, Paramsothy P, Bourne A, Gill EA. Carotid intima-media thickness for the practicing lipidologist. J Clin Lipidol. 2010;4(1):24–35. [PubMed] 541. Goldberger ZD, Valle JA, Dandekar VK, et al. Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis. Amer Heart J. 2010;160(4):701–714. [PubMed] 542. Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010;55(15):1600–1607. [PMC free article] [PubMed] 543. Gerber TC, Taylor AJ. Carotid intima-media thickness: can it close the “detection gap” for cardiovascular risk? Mayo Clin Proc. 2009;84(3):218–220. [PMC free article] [PubMed] 544. Lester SJ, Eleid MF, Khandheria BK, Hurst RT. Carotid intima-media thickness and coronary artery calcium score as indications of subclinical atherosclerosis. Mayo Clin Proc. 2009;84(3):229–233. [PMC free article] [PubMed] 545. Stein JH, Johnson HM. Carotid intima-media thickness, plaques, and cardiovascular disease risk: implications for preventive cardiology guidelines. J Am Coll Cardiol. 2010;55(15):1608–1610. [PubMed] 546. Sibal L, Agarwal SC, Home PD. Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. Diab Metab Syndr Obesity. 2011;4:23–34. [PMC free article] [PubMed] 547. Sharma K, Blaha MJ, Blumenthal RS, Musunuru K. Clinical and Research applications of carotid intima-media thickness. Am J Cardiol. 2009;103(9):1316–1320. [PMC free article] [PubMed] 548. Costanzo P, Perrone-Filardi P, Vassallo E, et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol. 2010;56(24):2006–2020. [PubMed] 549. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. J Am Soc Echocardiogr. 2008;21(2):93–111. [PubMed] 550. United States Preventive Services Task Force Using nontraditional risk factors in coronary heart disease risk assessment: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2009;151(7):474–482. [PubMed] 551. Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303(16):1610–1616. [PMC free article] [PubMed] 552. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–1345. [PubMed] 553. Shah PK. The SHAPE Paradigm: a commentary. Circ Cardiovasc Qual Outcomes. 2010;3(1):106–109. [PubMed] 554. Patel A, Budoff M. Screening for heart disease: C-reactive protein versus coronary artery calcium. Expert Rev Cardiovasc Ther. 2010;8(1):125–131. [PubMed] 555. Erbel R, Möhlenkamp S, Moebus S, et al. for the Heinz Nixdorf Recall Study Investigative Group Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: The Heinz Nixdorf Recall Study. J Am Coll Cardiol. 2010;56(17):1397–1406. [PubMed] 556. Elias-Smale SE, Proença RV, Koller MT, et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly: The Rotterdam Study. J Am Coll Cardiol. 2010;56(17):1407–1414. [PubMed] 557. Duprez D. Coronary artery calcification, an improvement in risk classification: need for reappraisal? J Am Coll Cardiol. 2010;56(17):1415–1417. [PubMed] 558. Rumberger JA. Using noncontrast cardiac CT and coronary artery calcification measurements for cardiovascular risk assessment and management in asymptomatic adults. Vasc Health Risk Manag. 2010;6:579–591. [PMC free article] [PubMed] 559. Piers LH, Salachova F, Slart RHJA, et al. The role of coronary artery calcification score in clinical practice. BMC Cardiovascular Disorders. 2008;8:38. [PMC free article] [PubMed] 560. Raggi P, Gongora MC, Gopal A, Callister TQ, Budoff M, Shaw LJ. Coronary artery calcium to predict all-cause mortality in elderly men and women. J Am Coll Cardiol. 2008;52(1):17–23. [PubMed] 561. Sharma RK, Sharma RK, Voelker DJ, et al. Cardiac risk stratification: role of the coronary calcium score. Vasc Health Risk Manag. 2010;6:603–611. [PMC free article] [PubMed] 562. Naghavi M, Falk E, Hecht HS, Shah PK., For the SHAPE Task Force The First SHAPE (Screening for Heart Attack Prevention and Education) Guideline. Crit Pathw Cardiol. 2006;5(4):187–190. [PubMed]
564. Naghavi M, editor. Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment. New York: Humana Press/Springer-Verlag; 2011.
565. Nasir K, Michos ED, Blumenthal RS, Raggi P. Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III Guidelines. J Am Coll Cardiol. 2005;46(10):1931–1936. [PubMed] 566. Shaw LJ, Raggi P, Berman DS, Callister TQ. Coronary artery calcium as a measure of biologic age. Atherosclerosis. 2006;188(1):112–119. [PubMed] 567. Harvey S, Hecht HS. A zero coronary artery calcium score: priceless. J Am Coll Cardiol. 2010;55(11):1118–1120. [PubMed] 568. Kabul P, Douglas PS. Atherosclerosis imaging: prognostically useful or merely more of what we know? Circ Cardiovasc Imaging. 2009;2(2):150–160. [PubMed] 569. Richard Conti C. Is calcium scoring of the coronary arteries necessary for proper management of asymptomatic subjects with classic risk factors? Clin Cardiol. 2010;33(11):658–659. [PubMed] 570. Budoff MJ, Gupta M. Radiation exposure from cardiac imaging procedures: do the risks outweight the benefits? J Am Coll Cardiol. 56(9):712–714. [PubMed] 571. Chen J, Einstein AJ, Fazel R, et al. cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis. J Am Coll Cardiol. 2010;56(9):702–711. [PMC free article] [PubMed] 572. Gibbons RJ, Gerber TC. Calcium scoreing with computed tomography: what is the radiation risk? Arch Int Med. 2009;169(13):1185–1187. [PubMed] 573. Mccullough PA, Chinnaiyan KM. Annual progression of coronary calcification in trials of preventive therapies: a systematic review. Arch Int Med. 2009;169(22):2064–2070. [PubMed] 574. O’Malley PG. A double take on serial measurement of coronary artery calcification. Arch Int Med. 2009;169(22):2051–2052. [PubMed] 575. See R, Lindsey JB, Patel MJ, et al. Application of the screening for Heart Attack Prevention and Education Task Force Recommendations to an urban population: observations from the Dallas Heart Study. Arch Intern Med. 2008;168(10):1055–1062. [PubMed] 576. Pletcher MJ, Greenland P. Coronary calcium scoring and cardiovascular risk: the SHAPE of things to come. Arch Intern Med. 2008;168(10):1027–1028. [PubMed] 577. Ioannidis JPA, Tzoulaki I. What makes a good predictor? the evidence applied to coronary artery calcium score. JAMA. 2010;303(16):1646–1647. [PubMed] 578. Einstein A, Weiner S, Bernheim A, et al. Multiple testing, cumulative radiation dose, and clinical indications in patients undergoing myocardial perfusion imaging. JAMA. 2010;304(19):2137–2144. [PMC free article] [PubMed] 579. Eisenberg MJ, Afilalo JA, Lawler PR, Abrahamowicz M, Richard H, Pilote L. Cancer risk related to low-dose ionizing radiation from cardiac imaging in patients after acute myocardial infarction. CMAJ. 2011;182(4):430–436. [PMC free article] [PubMed] 580. Dorfman AL, Fazel R, Einstein AJ, et al. Use of medical imaging procedures with ionizing radiation in children: a population-based study. Arch Pediatr Adolesc Med. 2011;165(5):458–464. [PubMed] 581. Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med. 2009;361(9):849–857. [PubMed] 582. Sodickson A, Baeyens PF, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology. 2009;251(1):175–184. [PubMed] 583. Mark DB, Berman DS, Budoff MJ, et al. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert consensus document of coronary computed tomographic angiography: a report of the American College of Cardiology Foundation task force on expert consensus documents. J Am Coll Cardiol. 2010;55(23):2663–2699. [PubMed] 584. Sarwar A, Shaw LJ, Shapiro MD, et al. diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging. 2009;2(6):675–688. [PubMed] 585. Garcia MJ, Fuster V. An ounce of prevention with a calcium score scan? JACC Cardiovasc Imaging. 2009;2(6):689–691. [PubMed] 586. Cademartiri F, Maffei E, Palumbo A, et al. Coronary calcium score and computed tomography coronary angiography in high-risk asymptomatic subjects: assessment of diagnostic accuracy and prevalence of non-obstructive coronary artery disease. Eur Radiol. 2010;20(4):846–854. [PubMed] 587. Gottlieb I, Miller JM, Arbab-Zadeh A, et al. The absence of coronary calcification does not exclude obstructive coronary artery disease or the need for revascularization in patients referred for conventional coronary angiography. J Am Coll Cardiol. 2010;55(7):627–634. [PMC free article] [PubMed] 588. Redberg RF. What is the prognostic value of a zero calcium score? J Am Coll Cardiol. 2010;55(7):635–636. [PubMed] 589. Baumann BM, Chen EH, Mills AM, et al. Patient perceptions of computed tomographic imaging and their understanding of radiation risk and exposure. Ann Emerg Med. 2010 Dec 10; [Epub ahead of print]. [PubMed] 590. Berrington de Gonzalez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169(22):2071–2077. [PubMed] 591. Fernandez-Friera L, Garcia-Alvarez A, Bagheriannejad-Esfahani F, et al. diagnostic value of coronary artery calcium scoring in low-intermediate risk patients evaluated in the emergency department for acute coronary syndrome. Am J Cardiol. 2011;107(1):17–23. [PubMed] 592. Nabi F, Chang SM, Pratt CM, et al. Coronary artery calcium scoring in the emergency department: identifying which patients with chest pain can be safely discharged home. Ann Emerg Med. 2010;56(3):220–229. [PubMed] 593. Budoff MJ. Coronary calcium remains an effective filter for invasive angiography. J Am Coll Cardiol. 2010;56(7):613–614. [PubMed] 594. Orringer CE. The absence of coronary calcium: clinical and therapeutic implications for the clinical lipidologist. J Clin Lipidol. 2010;4(6):472–477. [PubMed]
595. Redberg RF. Reply. J Am Coll Cardiol. 2010;56(7):615–615.
596. McEvoy JW, Blaha MJ, DeFilippis AP, et al. Coronary artery calcium progression: an important clinical measurement? A review of published reports. J Am Coll Cardiol. 2010;56(20):1613–1622. [PubMed] 597. Heart Protection Study Collaborative Group Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2(2):65–72. [PubMed] 598. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152(2):69–77. [PubMed] 599. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959–1965. [PubMed] 600. Mahoney EM. Targeting patients for statin therapy for the primary prevention of vascular events: what is the best approach? Circulation. 2010;122(15):1446–1448. [PubMed] 601. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006;145(7):520–530. [PubMed] 602. Li M, Ong KL, Tse HF, Cheung BM. Utilization of lipid lowering medications among adults in the United States 1999–2006. Atherosclerosis. 2010;208(2):456–460. [PubMed] 603. Lewis LS. Strategies for statins: The CASE for fire and forget. BMJ. 2008;336(7641):406. [PMC free article] [PubMed] 605. Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Int Med. 2009;151(9):622–630. [PubMed] 606. Krumholz HM, Hayward RA. Shifting views on lipid lowering therapy. BMJ. 2010;341:c3531. [PubMed] 608. O’Keefe JH, Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43(11):2142–2146. [PubMed] 609. Hochholzer W, Giugliano RP. Lipid lowering goals: back to nature? Ther Adv Cardiovasc Dis. 2010;4(3):185–191. [PubMed] 610. O’Keefe H, Jr, Cordain L. Cardiovascular disease resulting from a diet and life-style at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer. Mayo Clin Proc. 2004;79(1):101–108. [PubMed] 611. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303(6797):276–282. [PMC free article] [PubMed] 612. Dietschy JM, Turley SD. thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res. 2004;45(8):1375–1397. [PubMed] 613. Drexel H, Aczel S, Marte T, Vonbank A, Saely CH. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. Atherosclerosis. 2010;208(2):484–489. [PubMed] 614. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80% BMJ. 2003;326(7404):1419. [PMC free article] [PubMed] 615. Yusuf S, Pais P, Afzal R, et al. the Indian Polycap Study (TIPS) Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672):1341–1351. [PubMed] 616. Cannon CP. Can the polypill save the world from heart disease? Lancet. 2009;373(9672):1313–1314. [PubMed] 617. Soliman EZ, Mendis S, Dissanayake WP, et al. A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization. Trials. 2011;12:3. [PMC free article] [PubMed] 618. Fuster V, Sanz G. A polypill for secondary prevention: time to move from intellectual debate to action. Nat Clin Pract Cardiovasc Med. 2007;4(4):173. [PubMed] 619. Fuster V. Prime time for a polypill after myocardial infarction? Nat Clin Pract Cardiovasc Med. 2009;6(2):83. [PubMed] 620. Wald NJ, Wald DS. The polypill concept. Heart. 2010;96(1):1–4. [PubMed] 621. Maciosek MV, Coffield AB, Flottemesch TJ, Edwards NM, Solberg LI. Greater Use Of Preventive Services In US Health Care Could Save Lives At Little Or No Cost. Health Affairs. 2010;29(9):1656–1660. [PubMed] 622. Webster R, Heeley E. Perceptions of risk: understanding cardiovascular disease. Risk Manag Healthc Policy. 2010;3:49–60. [PMC free article] [PubMed] 623. Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb KJ. Twelve-year follow-up of American women’s awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes. 2010;3(2):120–127. [PMC free article] [PubMed] 624. Pancioli AM, Broderick J, Kothari R, et al. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA. 1998;279(16):1288–1292. [PubMed]
625. Ritchie JE, Herscovitch F, Norfor JB. Beliefs of blue collar workers regarding coronary risk behaviours. Health Educ Res. 1994;9(1):95–103.
626. Norcross JC, Krebs PM, Prochaska JO. Stages of change. J Clin Psychol. 2011;67(2):143–154. [PubMed] 627. Janz NK, Becker MH. The Health Belief Model: a decade later. Health Educ Q. 1984;11(1):1–47. [PubMed] 628. Weinstein ND. Unrealistic optimism about susceptibility to health problems: conclusions from a community-wide sample. J Behav Med. 1987;10(5):481–500. [PubMed] 629. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update. A guideline from the American Heart Association. Circulation. 2011;123(11):1243–1262. [PMC free article] [PubMed] 630. Robins SJ, Lyass A, Zachariah JP, Massaro JM, Vasan RS. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2011;31(5):1208–1214. [PMC free article] [PubMed] 631. Möhlenkamp S, Lehmann N, Moebus S, et al. for the Heinz Nixdorf Recall Study Investigators Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol. 2011;57(13):1455–1464. [PubMed] 632. Hamm CW, Nef HM, Rolf A, Möllmann H. Calcium and C-reactive protein: hot enough to predict the future? J Am Coll Cardiol. 2011;57(13):1465–1467. [PubMed] 633. Chironi G, Simon A, Megnien J-L, et al. Coronary calcium data have limited impact on CHD risk-classification. Int J Cardiol. 2010 doi: 10.1016/j.ijcard.2010.05.024. advance publication. In press. [PubMed] [Cross Ref] 634. Rubin J, Chang H-J, Nasir K, et al. Association between high-sensitivity C-reactive protein and coronary plaque subtypes assessed by 64-slice coronary computed tomography angiography in an asymptomatic population. Circ Cardiovasc Imaging. 2011;4:201–209. [PubMed] 635. Ridker PM. High-sensitivity C-reactive protein, vascular imaging, and vulnerable plaque. More evidence to support trials of antiinflammatory therapy for cardiovascular risk reduction. Circ Cardiovasc Imaging. 2011;4:195–197. [PubMed] 636. deGoma EM, Rader DJ. Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol. 2011;8:266–277. [PMC free article] [PubMed] 637. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210(2):353–361. [PubMed]